Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy.

Abstract

BACKGROUND:

Although cardiac troponin is associated with outcomes in atrial fibrillation (AF), the complementary prognostic information provided by cardiac troponin I (cTnI) and cTnT is unknown. This study investigated the distribution, determinants, and prognostic value of cTnI and cTnT concentrations in patients with AF.

METHODS:

Samples were collected. At the time of randomization, we analyzed cTnI and cTnT concentrations of 14806 AF patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial using high-sensitivity assays. Correlations (Spearman), determinants (multivariable linear regression), and outcomes (adjusted Cox models and c-statistics) were investigated.

RESULTS:

Concentrations of cTnI and cTnT were correlated (r = 0.70) and measurable in most participants [cTnI 98.5% (median 5.4 ng/L, ≥99th percentile in 9.2%) and cTnT 93.5% (median 10.9 ng/L, ≥99th percentile in 34.4%)]. Renal impairment was the most important factor affecting the concentrations of both troponins. cTnI increase was more associated with heart failure, vascular disease, and persistent/permanent AF, and cTnT with age, male sex, and diabetes. Over a median 1.9 years of follow-up, patients with both troponins above the median had significantly higher risk for stroke/systemic embolism [hazard ratio (HR) 1.72 (95% CI 1.31-2.27)], cardiac death [3.14 (2.35-4.20)], and myocardial infarction [2.99 (1.78-5.03)] than those with both troponins below median (all P < 0.005). Intermediate risks were observed when only 1 troponin was above the median. When combined with clinical information, each marker provided similar prognostication and had comparable c-index.

CONCLUSIONS:

cTnI and cTnT concentrations are moderately correlated and measurable in plasma of most AF patients. The risk of stroke and cardiovascular events is highest when both troponins are above median concentrations. Each troponin provides comparable prognostic information when combined with clinical risk factors. ClinicalTrials.gov/NCT00412984.

• Authors: Ziad Hijazi, Agneta Siegbahn, Ulrika Andersson, Bertil Lindahl, Christopher B Granger, John H Alexander, Dan Atar, Bernard J Gersh, Michael Hanna, Veli-Pekka Harjola, John Horowitz, Steen Husted, Elaine M Hylek, Renato D Lopes, John J V McMurray, Lars Wallentin
• Journal: Clinical chemistry (Clin Chem) Vol. 61 Issue 2 Pg. 368-78 (Feb 2015) ISSN: 1530-8561 [Electronic] England
• PMID: 25451868 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2014 American Association for Clinical Chemistry.

Chemical References

• Troponin I
• Troponin T

Topics

• Aged
• Atrial Fibrillation (blood, complications, diagnosis)
• Cardiovascular Diseases (blood, diagnosis, etiology)
• Female
• Humans
• Male
• Middle Aged
• Prognosis
• Risk Factors
• Stroke (blood, diagnosis, etiology)
• Troponin I (blood)
• Troponin T (blood)